NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

Stock Information for NeuroOne Medical Technologies Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroOne Medical Technologies Corporation

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne® Issues Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.